HC Wainwright Expects Weaker Earnings for BioLife Solutions

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at HC Wainwright reduced their Q4 2025 earnings estimates for BioLife Solutions in a research report issued on Monday, November 24th. HC Wainwright analyst Y. Chen now expects that the medical equipment provider will earn ($0.05) per share for the quarter, down from their previous estimate of ($0.02). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.02) EPS.

A number of other brokerages have also recently weighed in on BLFS. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Finally, Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.20.

BioLife Solutions Stock Down 1.1%

Shares of NASDAQ BLFS opened at $26.68 on Wednesday. The stock has a market capitalization of $1.28 billion, a PE ratio of -222.31 and a beta of 1.97. The firm has a fifty day moving average of $26.44 and a 200-day moving average of $24.22. BioLife Solutions has a 52-week low of $19.10 and a 52-week high of $29.62.

Institutional Trading of BioLife Solutions

A number of hedge funds have recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in shares of BioLife Solutions by 3.5% during the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares during the period. Louisiana State Employees Retirement System increased its position in BioLife Solutions by 2.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after acquiring an additional 500 shares during the period. Isthmus Partners LLC raised its stake in BioLife Solutions by 0.4% during the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after acquiring an additional 509 shares in the last quarter. Finally, Sei Investments Co. boosted its position in BioLife Solutions by 0.5% during the 1st quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after acquiring an additional 547 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Activity

In other BioLife Solutions news, Director Amy Duross sold 4,523 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $24.51, for a total value of $110,858.73. Following the completion of the transaction, the director owned 25,687 shares in the company, valued at $629,588.37. This represents a 14.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Troy Wichterman sold 1,032 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total transaction of $27,688.56. Following the completion of the sale, the chief financial officer directly owned 184,186 shares of the company’s stock, valued at $4,941,710.38. This trade represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 901,524 shares of company stock worth $25,384,826 in the last ninety days. 2.20% of the stock is currently owned by company insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.